Authors: Kumar, CC Malkowski, M Yin, ZZ Tanghetti, E Yaremko, B Nechuta, T Varner, J Liu, M Smith, EM Neustadt, B Presta, M Armstrong, L

Citation: Cc. Kumar et al., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta(3) and alpha(v)beta(5) integrin receptor antagonist, CANCER RES, 61(5), 2001, pp. 2232-2238

Authors: Liu, M Bryant, MS Chen, JP Lee, SN Yaremko, B Li, ZJ Dell, J Lipari, P Malkowski, M Prioli, N Rossman, RR Korfmacher, WA Nomeir, AA Lin, CC Mallams, AK Doll, RJ Catino, JJ Girijavallabhan, VM Kirschmeier, P Bishop, WR

Citation: M. Liu et al., Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice, CANC CHEMOT, 43(1), 1999, pp. 50-58

Authors: Brassard, DL Maxwell, E Malkowski, M Nagabhushan, TL Kumar, CC Armstrong, L

Citation: Dl. Brassard et al., Integrin alpha(v)beta(3)-mediated activation of apoptosis, EXP CELL RE, 251(1), 1999, pp. 33-45

Authors: Nielsen, LL Shi, B Hajian, G Yaremko, B Lipari, P Ferrari, E Gurnani, M Malkowski, M Chen, JP Bishop, WR Liu, M

Citation: Ll. Nielsen et al., Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models, CANCER RES, 59(23), 1999, pp. 5896-5901